(1)路透社6月4日原報導可參考[1].
- The COVID-19 vaccine, known as UB-612, is being developed by a privately-held U.S. firm called COVAXX. The company has said the vaccine shows promise in protecting people against coronavirus, based on a small study of 60 patients in Taiwan. It hasn't provided data on safety and efficacy from large clinical trials, information that is usually required before a vaccine is authorized for public use….
- Data on how well the vaccine works is still pending. In an email to Reuters, Vaxxinity’s Murphy said the company had completed the Phase 1 trial of 60 volunteers aged 20 to 55 in Taiwan, and is conducting a new study of 3,800 people there, including teens and elderly participants. The company plans larger trials in Brazil and India later this year.
